Prices | Financials | Company Info | Reports
The milestone payments are part of a deal worth $613 million, which the Mumbai-based firm signed with the French firm in May 2011, for Sanofi to develop the new drug.
Glenmark, through its Swiss subsidiary, received the payment from Sanofi on a collaboration of its VLA2 (alpha2-beta1) integrin monoclonal antibody, the company said in a statement.
Glenmark has already received from Sanofi $50 million as upfront payment in 2011-12. The total amount received by Glenmark from Sanofi for the new drug is $55 million, the company said.
Glenmark shares closed at Rs 581.35 on the BSE, up 1.23 per cent.
Copyright © 2014 Times Internet Limited. All rights reserved.
via Business - Google News http://ift.tt/1hI22jh
Put the internet to work for you.

0 comments:
Post a Comment